Annual Report 2023

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2023 88 The United Laboratories International Holdings Limited Annual Report 2023 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information (Continued) (b) Other segment information (Continued) For the year ended 31 December 2022 Intermediate Bulk Finished products medicine products Unallocated Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Amortisation of intangible assets 1,840 – 17,648 – 19,488 Depreciation of right-of-use assets 3,203 5,065 1,511 1,330 11,109 Depreciation of property, plant and equipment 379,587 85,602 51,912 4,733 521,834 Net loss on disposal of property, plant and equipment 2,194 2,049 147 – 4,390 Written off of property, plant and equipment 32,265 29,208 330 16,373 78,176 Impairment losses (reversed) recognised (5,746) (3,761) 1,260 (3,471) (11,718) (c) Geographical information The revenue by geographical market (irrespective of the origin of the goods) based on the location of the customers are presented below: Revenue from external customers 2023 2022 RMB’000 RMB’000 PRC, including Hong Kong (country of domicile) 11,124,265 8,962,740 Europe 783,732 631,282 India 673,922 556,336 Middle East 46,834 48,294 South America 340,391 297,594 Other Asian regions 603,726 587,835 Other regions 167,009 250,181 13,739,879 11,334,262